MTST (MetaStat) Cyclically Adjusted PB Ratio: (As of Jul. 11, 2026)


What is MetaStat Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MetaStat  (OTCPK:MTST) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MetaStat Cyclically Adjusted PB Ratio Related Terms


MetaStat Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for MetaStat's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Cyclically Adjusted PB Ratio Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, MetaStat's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MetaStat's Cyclically Adjusted PB Ratio falls into.



MetaStat Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MetaStat's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2018 is calculated as:

For example, MetaStat's adjusted Book Value per Share data for the three months ended in Feb. 2018 was:

Adj_Book=Book Value per Share/CPI of Feb. 2018 (Change)*Current CPI (Feb. 2018)
=-0.264/248.9910*248.9910
=-0.264

Current CPI (Feb. 2018) = 248.9910.

MetaStat Quarterly Data

Book Value per Share CPI Adj_Book
200805 6.879 216.632 7.907
200808 1.939 219.086 2.204
200811 -1.939 212.425 -2.273
200902 -2.424 212.193 -2.844
200905 -2.879 213.856 -3.352
200908 -3.424 215.834 -3.950
200911 -4.030 216.330 -4.638
201002 -5.273 216.741 -6.058
201005 -6.303 218.178 -7.193
201008 -6.818 218.312 -7.776
201011 -7.394 218.803 -8.414
201102 7.667 221.309 8.626
201105 -8.909 225.964 -9.817
201108 -9.424 226.545 -10.358
201111 -9.909 226.230 -10.906
201202 1.099 227.663 1.202
201205 1.403 229.815 1.520
201208 0.811 230.379 0.877
201211 0.518 230.221 0.560
201302 0.097 232.166 0.104
201305 -0.118 232.945 -0.126
201308 -0.532 233.877 -0.566
201311 -1.010 233.069 -1.079
201402 -1.447 234.781 -1.535
201405 -2.205 237.900 -2.308
201408 0.462 237.852 0.484
201411 0.095 236.151 0.100
201502 0.133 234.722 0.141
201505 0.641 237.805 0.671
201508 0.118 238.316 0.123
201511 -0.425 237.336 -0.446
201602 -0.956 237.111 -1.004
201605 -1.373 240.229 -1.423
201608 -1.353 240.849 -1.399
201611 -0.784 241.353 -0.809
201702 -0.594 243.603 -0.607
201705 -0.318 244.733 -0.324
201708 0.018 245.519 0.018
201711 -0.134 246.669 -0.135
201802 -0.264 248.991 -0.264

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.